Bevacizumab

Human normal lung epithelial cells (NL20, ATCC, Manassas, VA) were cultured using airway epithelial cell basal medium containing Bronchial epithelial growth kit (ATCC, Manassas, VA). Human normal lung fibroblast (MrC5, ATCC, Manassas, VA) were grown in Fibroblast basal media containing 10% FBS. Human umbilical vein endothelial cells and human normal lymphatic endothelial cells were grown in endothelial basal medium (EBM, Lonza, Allendale, NJ) containing endothelial growth factor (EGM-2 bullet kit, Lonza, Allendale, NJ). The cancer cell lines were obtained from ATCC and cultured in appropriate media. A2780 and cisplatin resistant A2780/C30 were gifted by Dr. Andrew Godwin. The established cell lines were validated by STR analyses. For 2D culture, cells were trypsinized and plated in the adherent cell culture treated plate. Single cell organoids were grown using DMEM containing rhEGF (20ng/ml), rhFGF (20ng/ml), 1X B27, and Heparin calcium salt (0.4%) from ThermoFisher Scientific, Grand Island, NY) in ultra-low attachment plates (Corning, Tewksbury, MA). All the compounds were obtained from Tocris Bioscience (Minneapolis, MN) or Sigma-Aldrich (St Louis, MO). Bevacizumab was obtained from BioRad (Hercules, CA).